Nucala (mepolizumab) gains FDA approval for two new self-administration options

GlaxoSmithKline (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) has approved two new methods for administering Nucala (mepolizumab), an autoinjector and a pre-filled safety syringe, for patients or caregivers to administer once every four weeks, after a healthcare professional decides it is appropriate.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news